Media & Press2019-09-17T16:08:49-04:00

    Bexion Pharmaceuticals Announces the Addition of Dr. Raymond J. Tesi to Board of Directors

    November 16, 2020|

    FOR IMMEDIATE RELEASE Covington, KY November 16, 2020               Bexion Pharmaceuticals, Inc. announced today that it has added RJ. Tesi, M.D. to its Board of Directors. Dr. Tesi has a distinguished career as a biotech entrepreneur and an experienced surgeon. Currently, he is President, Chief Executive Officer and acting Chief Medical Officer of INmune Bio (NASDAQ: ... Read More

      Bexion Pharmaceuticals, Inc. Receives Rare Pediatric Disease Designation

      September 30, 2020|

      FOR IMMEDIATE RELEASE [Covington, KY] September 30, 2020 Bexion Pharmaceuticals, Inc., a clinical stage biotechnology company focused on developing innovative cures for cancer, announced that the Federal Drug Administration (FDA) has granted the company’s request for rare pediatric disease designation for BXQ-350, Bexion’s lead therapeutic, for the treatment of diffuse intrinsic pontine glioma (DIPG) and ... Read More

        Bexion Pharmaceuticals, Inc. to Present Clinical and Pre-Clinical Data at 2020 SNO Annual Meeting

        September 16, 2020|

        FOR IMMEDIATE RELEASE [Covington, KY: September 16, 2020] Bexion Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative cures for cancer announced today it will present clinical and pre-clinical electronic posters with audio presentations at the Society of Neuro-Oncology (SNO) annual virtual conference to be held November 19-21, 2020. "We ... Read More

        All Press